0001354457-23-000878.txt : 20231120
0001354457-23-000878.hdr.sgml : 20231120
20231120084943
ACCESSION NUMBER: 0001354457-23-000878
CONFORMED SUBMISSION TYPE: 25-NSE
CONFIRMING COPY:
PUBLIC DOCUMENT COUNT: 2
FILED AS OF DATE: 20231120
DATE AS OF CHANGE: 20231120
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: Acer Therapeutics Inc.
CENTRAL INDEX KEY: 0001069308
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 320426967
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 25-NSE
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33004
BUSINESS ADDRESS:
STREET 1: ONE GATEWAY CENTER (300 WASHINGTON ST.)
STREET 2: SUITE 356
CITY: NEWTON
STATE: MA
ZIP: 02458
BUSINESS PHONE: (844) 902-6100
MAIL ADDRESS:
STREET 1: ONE GATEWAY CENTER (300 WASHINGTON ST.)
STREET 2: SUITE 356
CITY: NEWTON
STATE: MA
ZIP: 02458
FORMER COMPANY:
FORMER CONFORMED NAME: Opexa Therapeutics, Inc.
DATE OF NAME CHANGE: 20060616
FORMER COMPANY:
FORMER CONFORMED NAME: PharmaFrontiers Corp.
DATE OF NAME CHANGE: 20051011
FORMER COMPANY:
FORMER CONFORMED NAME: PHARMAFRONTIERS CORP
DATE OF NAME CHANGE: 20040816
FILED BY:
COMPANY DATA:
COMPANY CONFORMED NAME: Nasdaq Stock Market LLC
CENTRAL INDEX KEY: 0001354457
IRS NUMBER: 521165937
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 25-NSE
BUSINESS ADDRESS:
STREET 1: One Liberty Plaza
CITY: New York
STATE: NY
ZIP: 10006
BUSINESS PHONE: 301-978-4144
MAIL ADDRESS:
STREET 1: Office of General Counsel
STREET 2: 805 King Farm Blvd.
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
FORMER COMPANY:
FORMER CONFORMED NAME: The Nasdaq Stock Market LLC
DATE OF NAME CHANGE: 20060224
25-NSE
1
primary_doc.xml
X0203
0001354457
Nasdaq Stock Market LLC
0001069308
Acer Therapeutics Inc.
001-33004
300 Washington St.
One Gateway Center, Suite 351
Newton
MA
MASSACHUSETTS
02458
(844) 902-6100
Common Stock
17 CFR 240.12d2-2(b)
Aravind Menon
Hearings Advisor
2023-11-20
EX-99.25
2
acerdelistreason.txt
Delisting Determination, The Nasdaq Stock Market, LLC, November 20, 2023,
Acer Therapeutics Inc.
The Nasdaq Stock Market LLC (the Exchange) has determined to remove
from listing the securities of Acer Therapeutics Inc., effective
at the opening of the trading session on November 30, 2023.
Based on review of information provided by the Company, Nasdaq
Staff determined that the Company no longer qualified for listing
on the Exchange pursuant to Listing Rule 5550(b)(2).
The Company was notified of the Staff determination on October 31, 2023.
The Company did not appeal the Staff determination to the Hearings Panel.
The Company securities were suspended on November 9, 2023. The Staff
determination to delist the Company securities became final on
November 9, 2023.